Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Plantar Fasciitis

In brief

The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.

Key facts

Study ID

NCT03137407

Run by

Revance Therapeutics, Inc.

People needed

59

Starts

2017-06-12

Expected to finish

2018-02-20

Last updated by the study team

2023-09-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent, including authorization to release health information
• Male or female subjects 18 to 65 years of age with diagnosis of plantar fasciitis
• Persistent heel pain for more than three months
• Women of child bearing potential must have negative pregnancy test at Screening and Injection Visits and must use an effective method of birth control during the course of the study

You may not qualify if…

• Previous surgery on the midfoot or hindfoot
• Neuromuscular disease
• Systemic muscle weakness
• Planning a pregnancy during the study
• Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to first visit

Where it is running

• Village Podiatry Centers — Duluth, Georgia, United States
• Weil Foot and Ankle Institute — Des Plaines, Illinois, United States
• Kansas City Bone & Joint Clinic — Overland Park, Kansas, United States
• Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States
• Element Research Group — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.